Control of chemotherapy-induced diarrhea with the synthetic enkephalin BW942C

A randomized trial with placebo in patients receiving cisplatin

M. G. Kris, Richard J. Gralla, R. A. Clark, L. B. Tyson, S. Groshen

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Diarrhea commonly occurs following the administration of cisplatin. BW942C, a pentapeptide, is a synthetic enkephalin shown to control castor oil-induced and traveler's diarrhea. To assess the safety and efficacy of BW942C in controlling diarrhea caused by cisplatin, 30 adults with lung cancer who had already experienced diarrhea (three or more loose bowel movements) during the 24-hour period following a prior cisplatin administration were randomized to receive either BW942C or placebo during the next cisplatin course. All patients received a concomitant antiemetic regimen including metoclopramide, dexamethasone, and lorazepam during all courses. Patients administered BW942C experienced less diarrhea (27% v 67%, P = .02). Twenty-seven percent of patients given the pentapeptide had loose bowel movements as opposed to 93% who received placebo (P = .0002). There were no significant differences in the incidence and degree of vomiting and other treatment-related side effects observed between the placebo and treatment groups. We conclude that oral BW942C is more effective than placebo in controlling diarrhea following cisplatin chemotherapy.

Original languageEnglish (US)
Pages (from-to)663-668
Number of pages6
JournalJournal of Clinical Oncology
Volume6
Issue number4
StatePublished - 1988
Externally publishedYes

Fingerprint

Enkephalins
Cisplatin
Diarrhea
Placebos
Drug Therapy
Castor Oil
Lorazepam
Metoclopramide
Antiemetics
Dexamethasone
Vomiting
Lung Neoplasms
Safety
Incidence
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Control of chemotherapy-induced diarrhea with the synthetic enkephalin BW942C : A randomized trial with placebo in patients receiving cisplatin. / Kris, M. G.; Gralla, Richard J.; Clark, R. A.; Tyson, L. B.; Groshen, S.

In: Journal of Clinical Oncology, Vol. 6, No. 4, 1988, p. 663-668.

Research output: Contribution to journalArticle

@article{bc2e4dae565a456380915c6176635985,
title = "Control of chemotherapy-induced diarrhea with the synthetic enkephalin BW942C: A randomized trial with placebo in patients receiving cisplatin",
abstract = "Diarrhea commonly occurs following the administration of cisplatin. BW942C, a pentapeptide, is a synthetic enkephalin shown to control castor oil-induced and traveler's diarrhea. To assess the safety and efficacy of BW942C in controlling diarrhea caused by cisplatin, 30 adults with lung cancer who had already experienced diarrhea (three or more loose bowel movements) during the 24-hour period following a prior cisplatin administration were randomized to receive either BW942C or placebo during the next cisplatin course. All patients received a concomitant antiemetic regimen including metoclopramide, dexamethasone, and lorazepam during all courses. Patients administered BW942C experienced less diarrhea (27{\%} v 67{\%}, P = .02). Twenty-seven percent of patients given the pentapeptide had loose bowel movements as opposed to 93{\%} who received placebo (P = .0002). There were no significant differences in the incidence and degree of vomiting and other treatment-related side effects observed between the placebo and treatment groups. We conclude that oral BW942C is more effective than placebo in controlling diarrhea following cisplatin chemotherapy.",
author = "Kris, {M. G.} and Gralla, {Richard J.} and Clark, {R. A.} and Tyson, {L. B.} and S. Groshen",
year = "1988",
language = "English (US)",
volume = "6",
pages = "663--668",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - Control of chemotherapy-induced diarrhea with the synthetic enkephalin BW942C

T2 - A randomized trial with placebo in patients receiving cisplatin

AU - Kris, M. G.

AU - Gralla, Richard J.

AU - Clark, R. A.

AU - Tyson, L. B.

AU - Groshen, S.

PY - 1988

Y1 - 1988

N2 - Diarrhea commonly occurs following the administration of cisplatin. BW942C, a pentapeptide, is a synthetic enkephalin shown to control castor oil-induced and traveler's diarrhea. To assess the safety and efficacy of BW942C in controlling diarrhea caused by cisplatin, 30 adults with lung cancer who had already experienced diarrhea (three or more loose bowel movements) during the 24-hour period following a prior cisplatin administration were randomized to receive either BW942C or placebo during the next cisplatin course. All patients received a concomitant antiemetic regimen including metoclopramide, dexamethasone, and lorazepam during all courses. Patients administered BW942C experienced less diarrhea (27% v 67%, P = .02). Twenty-seven percent of patients given the pentapeptide had loose bowel movements as opposed to 93% who received placebo (P = .0002). There were no significant differences in the incidence and degree of vomiting and other treatment-related side effects observed between the placebo and treatment groups. We conclude that oral BW942C is more effective than placebo in controlling diarrhea following cisplatin chemotherapy.

AB - Diarrhea commonly occurs following the administration of cisplatin. BW942C, a pentapeptide, is a synthetic enkephalin shown to control castor oil-induced and traveler's diarrhea. To assess the safety and efficacy of BW942C in controlling diarrhea caused by cisplatin, 30 adults with lung cancer who had already experienced diarrhea (three or more loose bowel movements) during the 24-hour period following a prior cisplatin administration were randomized to receive either BW942C or placebo during the next cisplatin course. All patients received a concomitant antiemetic regimen including metoclopramide, dexamethasone, and lorazepam during all courses. Patients administered BW942C experienced less diarrhea (27% v 67%, P = .02). Twenty-seven percent of patients given the pentapeptide had loose bowel movements as opposed to 93% who received placebo (P = .0002). There were no significant differences in the incidence and degree of vomiting and other treatment-related side effects observed between the placebo and treatment groups. We conclude that oral BW942C is more effective than placebo in controlling diarrhea following cisplatin chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0023926925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023926925&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 663

EP - 668

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -